AB
CTMX icon

Amalgamated Bank’s CytomX Therapeutics CTMX Stock Holding History

Amalgamated Bank’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,184
Closed -$27K – 3066
2022
Q1 		$27K Sell
10,184
-818
-7% -$3.14K ﹤0.01% 2707
2021
Q4 		$48K Sell
11,002
-384
-3% -$2.25K ﹤0.01% 2111
2021
Q3 		$58K Sell
11,386
-396
-3% -$2.12K ﹤0.01% 2120
2021
Q2 		$75K Buy
+11,782
New +$91.7K ﹤0.01% 2135

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Bank's CTMX Position: Q2 2022 in Review

Amalgamated Bank sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 10,184 shares — an estimated $27K sold.

Amalgamated Bank first reported a position in CTMX in Q2 2021 and held it in 4 quarters. The position peaked at $75K in Q2 2021. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Amalgamated Bank reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Amalgamated Bank sold 10,184 CytomX Therapeutics shares in Q2 2022, an estimated $27K.
  • Amalgamated Bank first reported a position in CytomX Therapeutics in Q2 2021 and held it in 4 quarters.
  • Amalgamated Bank's CytomX Therapeutics position peaked at $75K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.